BAX
Baxter International Inc.Healthcare · $12.1B market cap
Verdict
We can't put a fair value on BAX right now. It lost money in at least 2 of its last 3 years, so one year of cash flow isn't a reliable base to value it on.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow BAX
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
7 of the investors we track hold BAX. In Q2 2026, 1 added and 1 trimmed. Who we track
Richard Pzena
Pzena Investment Management · as of Q2 2026
$1.4B
65,295,393 shares
Dodge & Cox Funds
Dodge & Cox Funds · as of Q2 2026
$1.2B
58,386,345 shares
Greenhaven Associates
Greenhaven Associates · as of Q2 2026
$304.6M
14,285,228 shares
First Pacific Advisors
First Pacific Advisors · as of Q2 2026
$162.4M
7,618,145 shares
Hillman Capital Management
Hillman Capital Management · as of Q2 2026
$5.0M
236,032 shares
Insider activity
Since Sep 1, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug…
Medical - Instruments & Supplies
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works